Vascular Considerations for Amyloid Immunotherapy

This article reviews the history of anti-Aβ immunotherapies and clinical findings and provides recommendations moving forward.Recent FindingsIn 20  years of both animal and human studies, anti-Aβ immunotherapies have been a prevalent avenue of reducing hallmark Aβ plaques. In both models and with different anti-Aβ antibody designs, amyloid-related imaging abnormalities (ARIA) indicating severe cerebrovascular compromise have been common an d concerning occurrence.SummaryARIA caused by anti-A β immunotherapy has been noted since the early 2000s, and the mechanisms driving it are still unknown. Recent approval of aducanumab comes with renewed urgency to consider vascular deficits caused by anti-Aβ immunotherapy.

Source: Current Neurology and Neuroscience Reports - October 21, 2022 Category: Neuroscience Source Type: research